Showing results (161-170 of 250) with videos related to
Sort By:
Pageof 25
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.Blood Neoplasia|June 2, 2025
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasmsBrady L Stein, Jason Gotlib, Murat Arcasoy, et al.Blood Advances|January 9, 2025
Advancing drug development in myelodysplastic syndromesAlain Mina, Kathy L McGraw, Lea Cunningham, et al.NEJM Evidence|February 6, 2024
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSKoji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, et al.Pageof 25